Knowles Corp
No enriched coverage for $KN in the last 7 days.
Knowles Corp (KN) director Cheryl L. Shavers sold 6,618 shares of common stock on August 17, 2026, at prices around $39.27–$39.28 per share. The amended Form 4/A clarifies these sales were not part of a Rule 10b5-1 trading plan, correcting a prior filing.
Knowles (NYSE:KN) is set to manufacture Elucent Medical’s smart surgical guidance device for the EnVisio In-Body Spatial Intelligence System, according to Elucent’s August 2026 announcement. The article says the work uses Knowles’ ISO 13485 and FDA-registered Penang facility. It also cites KN’s buybacks and forecast 2029 revenue of $815.9M and earnings of $135.8M.
Niew Jeffrey (President & CEO) sold 200,000 shares of Knowles Corp (KN) at an average of $38.95 ($38.00–$39.07, $7.79M total) across 3 trades over 2026-08-12 to 2026-08-14 under a Rule 10b5-1 trading plan.
Recent KN coverage spans financial news, insider activity and earnings.
In the last 30 days, KN insiders filed 7 SEC Form 4 transactions — no purchases and 7 sales ($9.6M). The most active reporter was Niew Jeffrey, President & CEO, with 3 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
The insider sale represents a modest $260K divestment with no new capital raise or strategic shift.
The contract supports Knowles’ MedTech manufacturing narrative, but the article provides no deal size or margin impact, limiting near-term earnings certainty.
This is a routine insider-sale disclosure with no stated operational or financial trigger, but it can still affect near-term sentiment.
This is a routine insider sale under a 10b5-1 plan, so it is more of a sentiment signal than a fundamental catalyst.
The article is an analyst target-price change for KN, which can drive near-term sentiment and positioning but is not a fundamental company disclosure.
alphai scores every news story that mentions KN with an AI model for sentiment and relevance, and aggregates insider trades from Knowles Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
Knowles Corp (KN) director Cheryl L. Shavers sold 6,618 shares of common stock on August 17, 2026, at prices around $39.27–$39.28 per share. The amended Form 4/A clarifies these sales were not part of a Rule 10b5-1 trading plan, correcting a prior filing.
1 min readKnowles (NYSE:KN) is set to manufacture Elucent Medical’s smart surgical guidance device for the EnVisio In-Body Spatial Intelligence System, according to Elucent’s August 2026 announcement. The article says the work uses Knowles’ ISO 13485 and FDA-registered Penang facility. It also cites KN’s buybacks and forecast 2029 revenue of $815.9M and earnings of $135.8M.
4 min readNiew Jeffrey (President & CEO) sold 200,000 shares of Knowles Corp (KN) at an average of $38.95 ($38.00–$39.07, $7.79M total) across 3 trades over 2026-08-12 to 2026-08-14 under a Rule 10b5-1 trading plan.
2 min readAnderson John S. (Senior Vice President & CFO) sold 40,000 shares of Knowles Corp (KN) at an average of $39.01 ($38.84–$39.07, $1.56M total) across 2 trades over 2026-08-12 to 2026-08-13 under a Rule 10b5-1 trading plan.
2 min readArgus issued a stock forecast for Knowles Corporation (KN), raising its target price to $46.00. The company manufactures micro-acoustic microphones, balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products.
1 min readConestoga Capital Advisors’ Q2 2026 investor letter said small caps improved, citing Russell 2000 and Russell 2000 Growth gains, but leadership was uneven. The firm added Knowles Corp (NYSE:KN) to its Small Cap Composite, noting accelerating organic growth, expanding margins, and secular trends. It cited Precision Devices book-to-bill above 1.0x for six quarters. KN closed Aug 4 at $40.40.
3 min readAfter Microsoft’s results, investors focused on AI monetization. Amazon shares jumped 15.3% post-close as AWS revenue rose 37% YoY, fastest in 18 quarters, and AI and chips run rates topped $25B. Apple fell 7.4% on outlook concerns. Treasuries rose to 4.71% and Brent to $87.93. The piece also lists options trades including LWLG and SITE.
7 min readKnowles reported Q2 revenue growth driven by demand across Precision Devices and Medtech & Specialty Audio, citing gains in medtech, defense, industrial and electrification, plus a strong backlog and design wins, according to management. CEO Jeffrey Niew said Q4 Medtech growth may slow due to earlier inventory build, while Precision Devices should keep momentum. The article notes margin expansion from productivity and mix, and mentions shares at $35.80.
4 min readKnowles Corporation reported Q2 2026 revenue up 14% year over year and higher earnings per share, according to the company’s results for the quarter ended June 30, 2026. The update indicates improving top-line performance and profitability for investors tracking KN’s quarterly financials.
2 min readCabrera Raymond D. (SVP, Chief HR Officer) sold 6,178 shares of Knowles Corp (KN) at $36.28 ($0.22M total) on 2026-07-27.
2 min read
